PI3K is a prominent pharmacological target for cancer treatment along the PAM pathway because of its remarkable correlation between hyperactivity and the evolution of human tumors, the production of boosted tumor microvessels, and a rise in the number of invasive cancer cells. Here, PIK3CB is linked to neoplasm.